0.7463
전일 마감가:
$0.7495
열려 있는:
$0.7569
하루 거래량:
948.35K
Relative Volume:
0.47
시가총액:
$138.89M
수익:
$90.12M
순이익/손실:
$-276.06M
주가수익비율:
-0.5112
EPS:
-1.46
순현금흐름:
$-193.47M
1주 성능:
+6.72%
1개월 성능:
-0.76%
6개월 성능:
-26.83%
1년 성능:
-46.69%
넥타테라퓨틱스 Stock (NKTR) Company Profile
명칭
Nektar Therapeutics
전화
(415) 482-5300
주소
455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA
NKTR을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
NKTR
Nektar Therapeutics
|
0.7463 | 130.14M | 90.12M | -276.06M | -193.47M | -1.46 |
![]()
ONC
Beone Medicines Ltd Adr
|
258.27 | 26.01B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
445.85 | 114.30B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
AKTX
Akari Therapeutics Plc Adr
|
1.3499 | 41.83M | 0 | 0 | 0 | 0.00 |
![]()
VRNA
Verona Pharma Plc Adr
|
83.98 | 6.29B | 0 | -153.72M | -103.81M | -2.00 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
484.93 | 63.90B | 14.09B | 4.50B | 2.96B | 39.28 |
넥타테라퓨틱스 Stock (NKTR) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-04-11 | 업그레이드 | Jefferies | Hold → Buy |
2025-03-14 | 업그레이드 | Oppenheimer | Perform → Outperform |
2025-01-08 | 개시 | B. Riley Securities | Buy |
2024-12-10 | 개시 | H.C. Wainwright | Buy |
2024-11-04 | 개시 | Piper Sandler | Overweight |
2024-09-30 | 재개 | BTIG Research | Buy |
2024-06-28 | 개시 | Rodman & Renshaw | Buy |
2023-11-20 | 재개 | JP Morgan | Underweight |
2023-11-09 | 업그레이드 | TD Cowen | Market Perform → Outperform |
2023-05-10 | 업그레이드 | Jefferies | Underperform → Hold |
2023-02-24 | 다운그레이드 | Jefferies | Hold → Underperform |
2022-08-08 | 다운그레이드 | JP Morgan | Neutral → Underweight |
2022-05-31 | 재개 | Jefferies | Hold |
2022-04-18 | 다운그레이드 | Goldman | Neutral → Sell |
2022-03-15 | 다운그레이드 | Cowen | Outperform → Market Perform |
2022-03-15 | 다운그레이드 | Mizuho | Buy → Neutral |
2022-03-14 | 다운그레이드 | BTIG Research | Buy → Neutral |
2022-03-14 | 다운그레이드 | BofA Securities | Neutral → Underperform |
2022-03-14 | 다운그레이드 | Stifel | Buy → Hold |
2022-03-14 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
2022-03-09 | 업그레이드 | Oppenheimer | Perform → Outperform |
2021-11-08 | 업그레이드 | The Benchmark Company | Hold → Buy |
2021-09-10 | 개시 | BofA Securities | Neutral |
2021-06-28 | 업그레이드 | Stifel | Hold → Buy |
2021-05-18 | 재개 | Goldman | Neutral |
2021-02-22 | 다운그레이드 | The Benchmark Company | Buy → Hold |
2021-01-06 | 개시 | Stifel | Hold |
2020-09-14 | 개시 | JP Morgan | Neutral |
2020-06-10 | 다운그레이드 | CFRA | Hold → Sell |
2020-05-12 | 재확인 | H.C. Wainwright | Neutral |
2020-04-22 | 개시 | The Benchmark Company | Buy |
2020-03-30 | 업그레이드 | Goldman | Sell → Neutral |
2020-03-04 | 개시 | Barclays | Overweight |
2020-02-03 | 업그레이드 | Mizuho | Neutral → Buy |
2019-10-24 | 개시 | Oppenheimer | Perform |
2019-10-08 | 다운그레이드 | Goldman | Buy → Sell |
2019-08-09 | 다운그레이드 | JP Morgan | Overweight → Neutral |
2019-08-09 | 다운그레이드 | Jefferies | Buy → Hold |
2019-08-09 | 다운그레이드 | Mizuho | Buy → Neutral |
2019-03-15 | 개시 | SVB Leerink | Mkt Perform |
2018-12-13 | 개시 | Goldman | Buy |
2018-06-11 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
2018-06-04 | 재확인 | H.C. Wainwright | Buy |
2018-04-20 | 개시 | Seaport Global Securities | Buy |
2018-04-13 | 재개 | Piper Jaffray | Overweight |
2018-04-06 | 재확인 | Mizuho | Buy |
2018-04-02 | 재개 | H.C. Wainwright | Buy |
모두보기
넥타테라퓨틱스 주식(NKTR)의 최신 뉴스
Nektar Therapeutics Approves Reverse Stock Split - TipRanks
Millennium Management LLC Sells 536,773 Shares of Nektar Therapeutics (NASDAQ:NKTR) - Defense World
Natural Killer (NK)-Cell Lymphoma Pipeline Appears Robust With 100+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Globe and Mail
D. E. Shaw & Co. Inc. Grows Stake in Nektar Therapeutics (NASDAQ:NKTR) - Defense World
Metastatic renal cell carcinoma Pipeline 2025: Groundbreaking - openPR.com
BNP Paribas Financial Markets Acquires 73,847 Shares of Nektar Therapeutics (NASDAQ:NKTR) - Defense World
Nektar Therapeutics Elects New Board, Approves Key Proposals - TipRanks
Natural Killer (NK)-Cell Lymphoma Market to Expand - openPR.com
Natural Killer (NK)-Cell Lymphoma Market to Expand Significantly by 2032, States DelveInsight Report | Innate Pharma, Nektar Therapeutics, ImmunityBio, CytoVac, Celularity - The Globe and Mail
Have Insiders Sold Nektar Therapeutics Shares Recently? - simplywall.st
Nektar Therapeutics (NASDAQ:NKTR) Receives $4.50 Average Target Price from Analysts - Defense World
Moderate to Severe Atopic Dermatitis Clinical Trial Pipeline Insights Featuring 45+ Companies | DelveInsight - GlobeNewswire
Nektar Therapeutics To Present At H.C. Wainwright BioConnect Conference; Webcast At 1:30 PM ET - Nasdaq
Nektar therapeutics outlines REZOLVE-AD phase 2b data and financial position for Q2 2025 - MSN
Nektar Therapeutics (NASDAQ:NKTR) Rating Lowered to “Sell” at StockNews.com - Defense World
What is William Blair’s Estimate for NKTR Q2 Earnings? - Defense World
Nektar Therapeutics (NASDAQ:NKTR) Analysts Are More Bearish Than They Used To Be - simplywall.st
Voya Investment Management LLC Acquires 121,187 Shares of Nektar Therapeutics (NASDAQ:NKTR) - Defense World
Q2 EPS Estimate for Nektar Therapeutics Decreased by Analyst - Defense World
GSK’s liver asset play grows group of $1B upfront deals - biocentury.com
Nektar Therapeutics (NASDAQ:NKTR) Analysts Are Cutting Their Estimates: Here's What You Need To Know - Yahoo Finance
Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference - Kilgore News Herald
Nektar Therapeutics to Participate in the H.C. Wainwright 3rd An - GuruFocus
Nektar Q1 Loss Wider Than Expected, Revenues Fall Y/Y, Stock Down - MSN
Time To Worry? Analysts Are Downgrading Their Nektar Therapeutics (NASDAQ:NKTR) Outlook - Yahoo Finance
Nektar Therapeutics’ (NKTR) Market Perform Rating Reaffirmed at William Blair - Defense World
Anticipated Clinical Trial Results and Financial Stability Justify Buy Rating for Nektar Therapeutics - TipRanks
H.C. Wainwright Reiterates Buy Rating on Nektar Therapeutics (NKTR) - StreetInsider
Nektar Therapeutics (NASDAQ:NKTR) Stock Position Raised by Wells Fargo & Company MN - Defense World
Barclays PLC Sells 32,476 Shares of Nektar Therapeutics (NASDAQ:NKTR) - Defense World
Dendrimers And Polymer Drugs Conjugate Market to Witness - openPR.com
H.C. Wainwright maintains NKTR stock Buy rating, $6.50 target - Investing.com
Nektar Therapeutics (NASDAQ:NKTR) Consensus Forecasts Have Become A Little Darker Since Its Latest Report - simplywall.st
Nektar Therapeutics First Quarter 2025 Earnings: Misses Expectations - Yahoo Finance
Nektar Therapeutics (NASDAQ:NKTR) Q1 2025 Earnings Call Transcript - Insider Monkey
Nektar Therapeutics’ Earnings Call Highlights Progress and Challenges - TipRanks
BTIG maintains Buy on Nektar stock, price target at $4.00 By Investing.com - Investing.com India
Insiders Sold Nektar Therapeutics At US$1.06, Meanwhile Stock Sits Near US$0.62 - simplywall.st
NEKTAR THERAPEUTICS SEC 10-Q Report - TradingView
BTIG Reiterates Buy Rating on Nektar Therapeutics (NKTR) - StreetInsider
Nektar Therapeutics (NKTR) Q1 2025 Earnings Call Highlights: Advancements in Immunology and ... By GuruFocus - Investing.com Canada
Nektar Therapeutics (NKTR) Q1 2025 Earnings Call Highlights: Advancements in Immunology and ... - Yahoo Finance
BTIG maintains Buy on Nektar stock, price target at $4.00 - Investing.com
Nektar Therapeutics (NKTR) Q1 2025 Earnings Call Highlights: Advancements in Immunology and Financial Outlook - GuruFocus
Nektar Therapeutics Reports Q1 2025 Financial Results - TipRanks
Q1 EPS Estimates for Nektar Therapeutics Lowered by B. Riley - Defense World
Earnings call transcript: Nektar misses Q1 2025 forecasts amid clinical progress - Investing.com
Nektar: Q1 Earnings Snapshot - The Washington Post
Nektar Therapeutics (NKTR) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
Nektar Therapeutics Q1 2025 Earnings: EPS Loss of $0.24 Misses E - GuruFocus
Nektar (NKTR) Reports Revenue Miss and Announces Key Study Timel - GuruFocus
넥타테라퓨틱스 (NKTR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):